We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-3.25 | -8.72% | 34.00 | 33.00 | 35.00 | 37.50 | 33.50 | 37.50 | 1,020,902 | 16:23:31 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -3.19M | -0.0469 | -7.25 | 23.14M |
TIDMSAR
RNS Number : 8859W
Sareum Holdings PLC
14 December 2023
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Results of AGM
Cambridge, UK, 14 December 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy.
Details of the proxy voting results are shown in the table below.
Ordinary Votes % Votes % Votes % Votes Resolutions For Against Total of Withheld ISC Voted 1. Receive the financial statements for the year 4,955,805 99.3% 33,480 0.7% 4,989,285 7.1% 2,917 ---------- ------ --------- ----- ---------- ------- ---------- 2. Receive and approve the Directors' Renumeration Report for the year 4,797,240 96.2% 187,995 3.8% 4,985,235 7.1% 6,967 ---------- ------ --------- ----- ---------- ------- ---------- 3. Re-elect Dr Timothy Mitchell as Director of the Company 4,723,539 94.9% 256,139 5.1% 4,979,678 7.1% 12,524 ---------- ------ --------- ----- ---------- ------- ---------- 4. Re-elect Dr Stephen Parker as Director of the Company 4,569,986 92.0% 399,292 8.0% 4,969,278 7.1% 22,924 ---------- ------ --------- ----- ---------- ------- ---------- 5. Re-appoint Shipleys LLP as auditor 4,855,004 98.1% 92,757 1.9% 4,947,761 7.0% 44,441 ---------- ------ --------- ----- ---------- ------- ---------- 6. Authorise the audit committee to determine auditor renumeration 4,867,151 98.3% 86,553 1.7% 4,953,704 7.1% 38,498 ---------- ------ --------- ----- ---------- ------- ---------- 7. Directors' authority to allot new shares 4,567,808 92.4% 373,843 7.6% 4,941,651 7.0% 50,551 ---------- ------ --------- ----- ---------- ------- ---------- Special Resolution ---------- ------ --------- ----- ---------- ------- ---------- 8. Directors' authority to disapply pre-emption rights 4,573,097 92.5% 368,554 7.5% 4,941,651 7.0% 50,551 ---------- ------ --------- ----- ---------- ------- ---------- 9. Authority to hold general meetings 4,926,142 99.0% 49,243 1.0% 4,975,385 7.1% 16,817 ---------- ------ --------- ----- ---------- ------- ----------
ISC - Issued Share Capital
The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website ( www.sareum.com/investors )
For further information, please contact:
Sareum Holdings plc Tim Mitchell, CEO 01223 497700 Lauren Williams, Head of Investor Relations ir@sareum.co.uk Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman 020 7409 3494 Peel Hunt LLP (Joint Corporate Broker) James Steel / Patrick Birkholm 020 7418 8900 Hybridan LLP (Joint Corporate Broker) Claire Noyce 020 3764 2341 ICR Consilium (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki 020 3709 5700
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
- Ends -
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGFFDFILEDSEDE
(END) Dow Jones Newswires
December 14, 2023 10:35 ET (15:35 GMT)
1 Year Sareum Chart |
1 Month Sareum Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions